A Phase 2 interventional study of LUM001 (Maralixibat) in Progressive Familial Intrahepatic Cholestasis (PFIC), sponsored by Mirum Pharmaceuticals, Inc.. Completed at 10 sites in 4 countries. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2023-10-23.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Cholestasis, progressive familial intrahepatic 1 · United States.
Among the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States, this one is one of 2 that started in 2014, is one of 2 in phase 2, and was the 3rd registered.
33 studies on the registry are indexed under Cholestasis, progressive familial intrahepatic 1; 13 are open to participants now.
Browse Cholestasis, progressive familial intrahepatic 1 studies →1 of the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States is open now. Recruiting first, the newest first:
Mirum Pharmaceuticals, Inc. · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Cholestasis, progressive familial intrahepatic 1 studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.
This study: 12 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2014.
This study's enrollment of 33 is below the median of 60 across 11 interventional studies indexed under Cholestasis, progressive familial intrahepatic 1.
Median enrollment 84 across the 5 interventional studies, 250 across the 4 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 5 most frequent:
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
Mirum Pharmaceuticals, Inc. has 8 studies filed under Cholestasis, progressive familial intrahepatic 1 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open label study in children with Progressive Familial Intrahepatic Cholestasis (PFIC) designed to evaluate the safety and efficacy of LUM001, also known as Maralixibat (MRX). Efficacy will be assessed by evaluating the effect of LUM001 on pruritus and the biochemical markers of pruritus associated with PFIC.
The study is divided into 5 parts: a 4-week dose escalation period, a 4-week stable dosing period, a 5-week stable dosing period, a 59-week long-term exposure period, and an optional follow-up treatment period for eligible participants who continue treatment with LUM001. Participants in the optional follow-up treatment period will continue to receive study drug until they are eligible to enter another LUM001 study or until LUM001 is available commercially, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evidence of chronic liver disease, excluding those listed in (see Section 16.3), with one or more of the following criteria:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive LUM001, also known as Maralixibat (MRX) twice a day (BID).
Drug: LUM001 (Maralixibat)
LUM001 also known as Maralixibat (MRX) oral dose up to twice a day (BID).
Change From Baseline to Endpoint (Week 13) in Fasting sBA Level
Time frame: Baseline (Day 0) to Week 13
Change From Baseline to Week 13/ET in Pruritus as Measured by ItchRO(Obs)
This secondary efficacy endpoint is the change from baseline to Week 13 in pruritus as measured by ItchRO(Obs) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).
Time frame: Baseline (Day 0) to Week 13
Change From Baseline to Week 13/ET in Pruritus as Measured by ItchRO(Pt)
This secondary efficacy endpoint is the change from baseline to Week 13 in pruritus as measured by ItchRO(Pt) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).
Time frame: Baseline (Day 0) to Week 13
Change From Baseline to Week 13/ET in ALT
Time frame: Baseline (Day 0) to Week 13
Change From Baseline to Week 13/ET in Total Bilirubin
Time frame: Baseline (Day 0) to Week 13
Change From Baseline to Week 13/ET in Direct Bilirubin
Time frame: Baseline (Day 0) to Week 13
A total of 33 participants were enrolled at 11 sites in 4 countries (US, UK, France, Poland). Participants included 19 females and 14 males ranging from 1 to 13 years of age. Screening, treatment and safety follow-up, was approximately 76 weeks after which participants had the option of continuing in the additional follow-up treatment period up to 287 weeks.
| Milestone | Progressive Familial Intrahepatic Cholestasis 1 (PFIC1) | Progressive Familial Intrahepatic Cholestasis 2 (PFIC2) (Overall) |
|---|---|---|
| Started | 8 | 25 |
| Completed study treatment through week 72 | 6 | 16 |
| Completed | 6 | 16 |
| Not completed | 2 | 9 |
| Withdrew: Progressive disease | 0 | 2 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Consent withdrawn by caregiver | 1 | 1 |
| Withdrew: Consent withdrawn by subject | 0 | 1 |
| Withdrew: Liver transplant | 0 | 1 |
| Milestone | Progressive Familial Intrahepatic Cholestasis 1 (PFIC1) | Progressive Familial Intrahepatic Cholestasis 2 (PFIC2) (Overall) |
|---|---|---|
| Started | 6 | 16 |
| Completed | 4 | 8 |
| Not completed | 2 | 8 |
| Withdrew: Did not consent to protocol amendment | 1 | 3 |
| Withdrew: Progressive disease | 0 | 1 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Liver transplant | 0 | 2 |
| umol/L | Maralixibat | PFIC1 | PFIC2 (Overall) |
|---|---|---|---|
| Change From Baseline to Endpoint (Week 13) in Fasting sBA Level | -23 (-463 to 279) | 18 (-117 to 149) | -38 (-463 to 279) |
This secondary efficacy endpoint is the change from baseline to Week 13 in pruritus as measured by ItchRO(Obs) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).
| scores on a scale | Maralixibat | PFIC1 | PFIC2 (Overall) |
|---|---|---|---|
| Change From Baseline to Week 13/ET in Pruritus as Measured by ItchRO(Obs) | -0.7 ± 0.65 | -0.8 ± 0.83 | -0.7 ± 0.59 |
This secondary efficacy endpoint is the change from baseline to Week 13 in pruritus as measured by ItchRO(Pt) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).
| scores on a scale | Maralixibat | PFIC1 | PFIC2 (Overall) |
|---|---|---|---|
| Change From Baseline to Week 13/ET in Pruritus as Measured by ItchRO(Pt) | -0.6 ± 0.57 | -0.4 ± 0.65 | -0.7 ± 0.57 |
| U/L | Maralixibat | PFIC1 | PFIC2 (Overall) |
|---|---|---|---|
| Change From Baseline to Week 13/ET in ALT | -9 ± 61.8 | -2 ± 29.1 | -11 ± 70.1 |
| mg/dL | Maralixibat | PFIC1 | PFIC2 (Overall) |
|---|---|---|---|
| Change From Baseline to Week 13/ET in Total Bilirubin | -0.2 ± 1.65 | -0.8 ± 2.95 | -0.0 ± 0.9 |
| mg/dL | Maralixibat | PFIC1 | PFIC2 (Overall) |
|---|---|---|---|
| Change From Baseline to Week 13/ET in Direct Bilirubin | -0.1 ± 1.12 | -0.3 ± 1.93 | -0.0 ± 0.72 |
Collected over Baseline to end of treatment (up to 287 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Population | 0/33 (0%) | 15/33 (45.5%) | 33/33 (100%) |
| Event | Safety Population |
|---|---|
| Abdominal painGastrointestinal disorders | 2/33 |
| DiarrhoeaGastrointestinal disorders | 2/33 |
| GastroenteritisInfections and infestations | 2/33 |
| Radius fractureInjury, poisoning and procedural complications | 1/33 |
| Ulna fractureInjury, poisoning and procedural complications | 1/33 |
| Upper limb fractureInjury, poisoning and procedural complications | 1/33 |
| Enteral nutritionSurgical and medical procedures | 1/33 |
| Gastrointestinal tube insertionSurgical and medical procedures | 1/33 |
| Blood bilirubin increasedInvestigations | 1/33 |
| International normalised ratio increasedInvestigations | 1/33 |
| Event | Safety Population |
|---|---|
| PyrexiaGeneral disorders | 20/33 |
| DiarrhoeaGastrointestinal disorders | 19/33 |
| CoughRespiratory, thoracic and mediastinal disorders | 18/33 |
| VomitingGastrointestinal disorders | 17/33 |
| Abdominal painGastrointestinal disorders | 15/33 |
| NasopharyngitisInfections and infestations | 15/33 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 13/33 |
| Upper respiratory tract infectionInfections and infestations | 11/33 |
| PruritusSkin and subcutaneous tissue disorders | 10/33 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 9/33 |
| Age, Customized(Subjects) | PFIC1 | PFIC2 (Overall) | Total |
|---|---|---|---|
| <2 years | 1 | 6 | 7 |
| 2 to 4 years | 5 | 10 | 15 |
| 5 to 8 years | 2 | 4 | 6 |
| 9 to 12 years | 0 | 4 | 4 |
| 13 to 18 years | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | PFIC1 | PFIC2 (Overall) | Total |
|---|---|---|---|
| Female | 2 | 17 | 19 |
| Male | 6 | 8 | 14 |
| Ethnicity (NIH/OMB)(Participants) | PFIC1 | PFIC2 (Overall) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 8 | 21 | 29 |
| Unknown or Not Reported | 0 | 3 | 3 |
| Race (NIH/OMB)(Participants) | PFIC1 | PFIC2 (Overall) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 6 | 20 | 26 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 3 | 3 |
| Region of Enrollment(participants) | PFIC1 | PFIC2 (Overall) | Total |
|---|---|---|---|
| United States | 5 | 10 | 15 |
| Poland | 0 | 1 | 1 |
| United Kingdom | 3 | 11 | 14 |
| France | 0 | 3 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2014 to primary completion in May 2020, 74 months.
Results were first posted in Jul 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat
Cholestasis, progressive familial intrahepatic 1 →